Biopharma's reset starts here

JANUARY 12 - 13, 2026 | 7:00 AM - 5:00 PM PT
MARRIOTT MARQUIS, SAN FRANCISCO

The easy money era is over in biopharma — but the deals haven't stopped. They've just gotten harder.

As the industry gathers in San Francisco for JPM, everyone's asking the same question: What actually works when capital is scarce and the old playbook is dead?

Join us for sessions that deliver unfiltered perspectives when the industry needs them most. Meanwhile, the Endpoints Hub offers a premium coworking lounge, a place to escape the noise, compare notes with peers who get it, and figure out your next move over breakfast, lunch, and real conversation.

Early Bird special rates:

Get your in-person ticket now and save 22% off single passes ($200 off)
NEW: Buy 3 passes and save 34% with Early Bird rates ($900 off)

RESERVE YOUR SPOT

Virtual passes available at no charge.
Going to be in SF? Save on all-access passes now with Early Bird.

ON THE AGENDA

NEW: Fireside chat with Frank Jiang, EVP and chief strategy officer at Jiangsu Hengrui Pharmaceuticals
Fireside chat with Eric Tokat, co-president of Centerview Partners
Featured conversation with Tony Wood, chief scientific officer at GSK

Our programming will decode the big questions facing biopharma in 2026. More details to come — stay tuned.

NEW: Frank Jiang,
EVP & Chief Strategy Officer
Jiangsu Hengrui Pharmaceuticals

Eric Tokat
Co-President
Centerview Partners

Tony Wood
Chief Scientific Officer
GSK

Endpoints at JPM26: Where biopharma goes to figure out what actually works now

We're drilling into the forces reshaping your business model: China's growing influence, regulatory upheaval, and a funding environment that's forcing everyone to rethink everything. How do we strike deals when buyers have all the leverage? Which strategies survive when funding plateaus? Find out — sign up now and be part of the action.